These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30845110)

  • 21. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 22. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 23. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 24. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 25. Bending the cost curve in cancer care.
    Good M; Good CB
    N Engl J Med; 2011 Aug; 365(7):674-5; author reply 675-6. PubMed ID: 21848478
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncology pharma costs to exceed $150 billion by 2020.
    Manag Care; 2016 Oct; 25(10):40. PubMed ID: 28121547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 29. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 30. Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.
    Foy R; So J; Rous E; Scarffe JH
    BMJ; 1999 Feb; 318(7181):456-9. PubMed ID: 9974468
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dose reassessment: An answer to the high cost of drugs used in oncology?].
    Levêque D
    Bull Cancer; 2019 Sep; 106(9):719-724. PubMed ID: 31202558
    [No Abstract]   [Full Text] [Related]  

  • 32. [Costs, disease management and DRG].
    Barni S; Mandalà M; Gambera M
    Tumori; 2001; 87(1 Suppl 1):S59. PubMed ID: 11300029
    [No Abstract]   [Full Text] [Related]  

  • 33. By the numbers: global oncology drug spending, 2010-2014.
    Cancer Discov; 2015 Aug; 5(8):790. PubMed ID: 26243858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Navigating the business of oncology for 2008.
    Crisafulli T
    Semin Oncol; 2008 Feb; 35(1):1-5. PubMed ID: 18308138
    [No Abstract]   [Full Text] [Related]  

  • 36. Robbing Peter to pay Paul? Financial reimbursement for chemotherapy.
    Arceci RJ
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):277-8. PubMed ID: 12679638
    [No Abstract]   [Full Text] [Related]  

  • 37. Value and payment for oncology in the United States.
    Robinson JC
    Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of value-based insurance design on oncology drugs.
    Fendrick AM
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):14-6. PubMed ID: 27057661
    [No Abstract]   [Full Text] [Related]  

  • 39. Can treatment costs be tamed?
    Malakoff D
    Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
    [No Abstract]   [Full Text] [Related]  

  • 40. Considerations in the Care of Non-Small-Cell Lung Cancer: The Value Imperative.
    Kelly R; Houseknecht S
    Oncology (Williston Park); 2018 Nov; 32(11):534-40. PubMed ID: 30474101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.